About gonshoham

This author has not yet filled in any details.
So far gonshoham has created 32 blog entries.

BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN HEAVILY PRETREATED MULTIPLE MYELOMA: OLD/NEW IN NOVEL AGENTS’ ERA

Cerchione, Claudio; Catalano, Lucio; Nappi, Davide; Rocco, Stefano; Palmieri, Salvatore; [...]

By |2021-05-01T04:20:52+00:00May 1st, 2021|Uncategorized|0 Comments

CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA

Cerchione, Claudio; Catalano, Lucio; Nappi, Davide; Pareto, Anna Emanuele; Musuraca, [...]

By |2021-05-01T05:32:00+00:00May 1st, 2021|Uncategorized|0 Comments

CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Jakubowiak, Andrzej; Berdeja, Jesus G; Usmani, Saad Z; Madduri, Deepu; [...]

By |2021-05-04T14:44:47+00:00May 1st, 2021|Uncategorized|0 Comments

CARTITUDE-2: PHASE 2 MULTICOHORT STUDY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A B-CELL MATURATION ANTIGEN (BCMA)–DIRECTED CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM)

Einsele, Hermann; van de Donk, Niels W.C.J.; Arnulf, Bertrand; Schecter, [...]

By |2021-05-04T14:49:58+00:00May 1st, 2021|Uncategorized|0 Comments

CYLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE VERSUS BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS : ASSESMENT OF THE 2016 VERSION TUNISIAN PROTOCOL

Belloumi, Dorra; Hasnaoui, Zaineb; Torjemane, Lamia; Ben Yaiche, Insaf; Ben [...]

By |2021-05-01T05:33:32+00:00May 1st, 2021|Uncategorized|0 Comments

CYTOKINE RELEASE SYNDROME (CRS) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN THE PHASE 1B/2 CARTITUDE-1 STUDY

Lin, Yi; Martin, Thomas; Cohen, Adam D; Jakubowiak, Andrzej; Jasielec, [...]

By |2021-05-04T14:50:46+00:00May 1st, 2021|Uncategorized|0 Comments

DARATUMUMAB PLUS BORTEZOMIB, MELPHALAN, AND PREDNISONE (D-VMP) VERSUS BORTEZOMIB, MELPHALAN, AND PREDNISONE (VMP) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS INELIGIBLE FOR TRANSPLANTATION: FRAILTY SUBGROUP ANALYSIS OF ALCYONE

Mateos, Maria-Victoria; Dimopoulos, Meletios A.; Cavo, Michele; Suzuki, Kenshi; Knop, [...]

By |2021-05-04T14:52:11+00:00May 1st, 2021|Uncategorized|0 Comments

DARATUMUMAB PLUS LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF GRIFFIN AFTER 12 MONTHS OF MAINTENANCE THERAPY

Voorhees, Peter; Laubach, Jacob; Sborov, Douglas; Reeves, Brandi; Rodriguez, Cesar; [...]

By |2021-05-04T14:52:43+00:00May 1st, 2021|Uncategorized|0 Comments

DARATUMUMAB SC + SOC IN MM ACROSS LINES OF THERAPY IN PHASE-2 PLEIADES: INITIAL RESULTS FOR DARATUMUMAB SC + CARFILZOMIB/DEXAMETHASONE AND UPDATED RESULTS FOR DARATUMUMAB SC + BORTEZOMIB/MELPHALAN/PREDNISONE OR LENALIDOMIDE/DEXAMETHASONE

Touzeau, Cyrille; Chari, Ajai; Haenel, Mathias; Oriol, Albert; Rodriguez-Otero, Paula; [...]

By |2021-05-01T05:33:53+00:00May 1st, 2021|Uncategorized|0 Comments
Go to Top